Table 1.

Patient details

Patient IDBRAF mutationType BRAF inhibitorDose at PRE/POST biopsy, mg bdDuration of treatment, daysChange in caliper size, %Change in PET SUVmax baseline to day 15Best CT responseBest CT lesion size change, %Time to progression, daysLast info statusTime to death, daysFollow-up period, days
1V600KGSK3534557−35CRa−100a119Alive574
2V600EGSK150154NAPR−76155Dead306306
3V600EGSK150274−25PR−71127Dead311311
4V600EGSK70482−100−55PR−63209Alive569
5V600KGSK150336NA−48PR−56118Dead543543
6V600ERoche960239UKPR−53239Alive525
7V600ERoche960348−11PR−46348Alive348
8V600EGSK20025327PR−42224Dead458458
9V600EGSK300131−73−66PR−36114Dead299299
10V600KGSK150216−28PR−31212Alive371
11V600EGSK100 mg tds91−11−25SD−1591Dead169169
12V600KGSK100229UK−64SD−14224Dead259259
13V600EGSK70223UKSD−10212Alive617
14V600EGSK100123−50−48SD−5117Dead214214
15V600EGSK2004345PD2943Dead8282

Abbreviations: CR, complete response; GSK, GSK2118436; PD, progressive disease; PR, partial response; Roche, PLX4720; SD, stable disease; and UK, unknown.

  • aPatient 1 had low-volume metastatic melanoma and was included in the phase I trial prior to the need for “measurable” disease. Of the 3 metastatic sites, 2 were resected during treatment as part of this TEAM study, and the remaining lesion was a deep muscular deposit seen on PET only. bd, twice a day; tds, 3 times a day.